552 results on '"Mascaux, Céline"'
Search Results
2. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC
3. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer
4. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
5. Cancer bronchique non à petites cellules : la place de l'immunothérapie chez le sujet âgé.
6. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
7. Immune evasion before tumour invasion in early lung squamous carcinogenesis
8. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer
9. Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non–Small Cell Lung Adenocarcinomas
10. Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer
11. Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
12. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model
13. A case of hepatitis induced by herbal medicine in non-small cell lung cancer patient treated by a combination of immunotherapy and chemotherapy
14. Contributors
15. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
16. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study
17. Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC)
18. The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?
19. Adjuvant Chemotherapy After Pulmonary Resection for Lung Cancer
20. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
21. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
22. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
23. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
24. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
25. Re: Two centres’ experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes
26. Abstract LB138: UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
27. Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
28. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC
29. Evasion before invasion: Pre-cancer immunosurveillance
30. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.
31. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
32. TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
33. Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.
34. Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project
35. 18 - Molecular Testing in Lung Cancer
36. Citation factors are not reflecting the methodological quality of lung cancer randomised trials
37. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis
38. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis
39. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer
40. Genomic Testing in Lung Cancer: Past, Present, and Future
41. Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma
42. Personalised medicine for nonsmall cell lung cancer
43. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
44. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
45. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature
46. Abstract 4478: EGFR tyrosine kinase inhibitors overcome resistance to chemotherapy in malignant pleural mesothelioma
47. Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party
48. Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma.
49. The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?
50. Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.